Law firm Pomerantz is investigating the claims

NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors in Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE:AMPE). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529 ext. 7980.

The investigation focuses on whether Ampio and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.

[Click here for information about joining the class action]

During premarket hours on August 3, 2022, Ampio issued a press release containing a letter to shareholders which disclosed that Ampio executives were aware, at the time of an interim per-protocol analysis in March 2020, that the the company‘s AP-013 clinical trial for its Ampion product did not demonstrate efficacy on its pain and function co-primary endpoints; and that company officials have not fully disclosed the results of the AP-013 trial and the timing of the unblinding of the AP-013 trial data.

On this news, Ampio’s stock price fell $0.06, or 35.38%, to close at $0.10 per share on August 3, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris and Tel Aviv, is recognized as one of the leading firms in the areas of corporate litigation, securities and antitrust. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he established, fighting for the rights of victims of securities fraud, breaches of fiduciary duty and corporate misconduct. The firm recovered numerous multimillion-dollar damages on behalf of class members. See

Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

About the author